Valneva SE (VLA.PA)
EUR 3.04
(1.13%)
EUR 3.04
(1.13%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 134.92 Million EUR | 1.54% |
| 2022 | 150.3 Million EUR | -32.16% |
| 2021 | 221.55 Million EUR | 99.37% |
| 2020 | 111.12 Million EUR | 44.42% |
| 2019 | 76.94 Million EUR | 21.49% |
| 2018 | 63.33 Million EUR | 0.11% |
| 2017 | 63.26 Million EUR | -32.29% |
| 2016 | 93.43 Million EUR | 81.9% |
| 2015 | 51.36 Million EUR | 17.98% |
| 2014 | 43.53 Million EUR | 20.75% |
| 2013 | 36.05 Million EUR | 121.67% |
| 2012 | 16.26 Million EUR | 88.09% |
| 2011 | 8.64 Million EUR | -48.57% |
| 2010 | 16.81 Million EUR | 397.1% |
| 2009 | 3.38 Million EUR | -11.63% |
| 2008 | 3.82 Million EUR | -3.55% |
| 2007 | 3.96 Million EUR | 117.54% |
| 2006 | 1.82 Million EUR | -54.01% |
| 2005 | 3.96 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 39.57 Million EUR | 0.01% |
| 2024 Q1 | 36.13 Million EUR | -20.13% |
| 2023 Q2 | 25.19 Million EUR | -14.87% |
| 2023 Q4 | 45.24 Million EUR | 14.86% |
| 2023 Q3 | 39.38 Million EUR | 56.31% |
| 2023 FY | 152.62 Million EUR | 1.54% |
| 2023 Q1 | 29.6 Million EUR | -35.7% |
| 2022 Q4 | 46.03 Million EUR | 43.14% |
| 2022 Q1 | 26.4 Million EUR | -64.16% |
| 2022 FY | 150.3 Million EUR | -32.16% |
| 2022 Q3 | 32.16 Million EUR | -29.62% |
| 2022 Q2 | 45.69 Million EUR | 73.04% |
| 2021 Q2 | 59.17 Million EUR | 49.03% |
| 2021 Q3 | 48.99 Million EUR | -17.2% |
| 2021 Q4 | 73.69 Million EUR | 50.42% |
| 2021 FY | 221.55 Million EUR | 99.37% |
| 2021 Q1 | 39.7 Million EUR | 13.67% |
| 2020 Q4 | 34.93 Million EUR | 26.97% |
| 2020 Q3 | 27.51 Million EUR | 7.29% |
| 2020 Q2 | 25.64 Million EUR | 11.26% |
| 2020 FY | 111.12 Million EUR | 44.42% |
| 2020 Q1 | 23.04 Million EUR | -10.37% |
| 2019 Q4 | 25.71 Million EUR | 42.3% |
| 2019 Q1 | 16.42 Million EUR | -9.68% |
| 2019 Q2 | 16.74 Million EUR | 1.95% |
| 2019 Q3 | 18.07 Million EUR | 7.93% |
| 2019 FY | 76.94 Million EUR | 21.49% |
| 2018 Q1 | 15.84 Million EUR | -16.14% |
| 2018 FY | 63.33 Million EUR | 0.11% |
| 2018 Q4 | 18.18 Million EUR | 45.65% |
| 2018 Q3 | 12.48 Million EUR | -25.83% |
| 2018 Q2 | 16.83 Million EUR | 6.26% |
| 2017 Q1 | 14.64 Million EUR | -10.16% |
| 2017 FY | 63.26 Million EUR | -32.29% |
| 2017 Q4 | 18.88 Million EUR | 12.6% |
| 2017 Q3 | 16.77 Million EUR | 29.48% |
| 2017 Q2 | 12.95 Million EUR | -11.54% |
| 2016 Q1 | 13.54 Million EUR | -5.63% |
| 2016 FY | 93.43 Million EUR | 81.9% |
| 2016 Q4 | 16.3 Million EUR | 15.4% |
| 2016 Q3 | 14.12 Million EUR | -71.43% |
| 2016 Q2 | 49.45 Million EUR | 265.05% |
| 2015 Q3 | 12.2 Million EUR | -15.79% |
| 2015 Q4 | 14.35 Million EUR | 17.64% |
| 2015 FY | 51.36 Million EUR | 17.98% |
| 2015 Q2 | 14.49 Million EUR | 40.46% |
| 2015 Q1 | 10.31 Million EUR | -27.8% |
| 2014 FY | 43.53 Million EUR | 20.75% |
| 2014 Q4 | 14.28 Million EUR | 82.14% |
| 2014 Q3 | 7.84 Million EUR | -28.87% |
| 2014 Q2 | 11.02 Million EUR | 6.35% |
| 2014 Q1 | 10.37 Million EUR | 41.11% |
| 2013 Q3 | 16.8 Million EUR | 98.42% |
| 2013 FY | 36.05 Million EUR | 121.67% |
| 2013 Q1 | 3.16 Million EUR | -29.28% |
| 2013 Q2 | 8.47 Million EUR | 167.98% |
| 2013 Q4 | 7.34 Million EUR | -56.28% |
| 2012 Q4 | 4.47 Million EUR | 29.83% |
| 2012 Q3 | 3.44 Million EUR | 0.0% |
| 2012 FY | 16.26 Million EUR | 88.09% |
| 2011 FY | 8.64 Million EUR | -48.57% |
| 2010 FY | 16.81 Million EUR | 397.1% |
| 2009 FY | 3.38 Million EUR | -11.63% |
| 2008 FY | 3.82 Million EUR | -3.55% |
| 2007 FY | 3.96 Million EUR | 117.54% |
| 2006 FY | 1.82 Million EUR | -54.01% |
| 2005 FY | 3.96 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -3130.166% |
| ABIVAX Société Anonyme | 127.37 Million EUR | -5.926% |
| Adocia SA | 15.62 Million EUR | -763.293% |
| Aelis Farma SA | 18.81 Million EUR | -616.956% |
| Biophytis S.A. | 14.33 Million EUR | -841.352% |
| Advicenne S.A. | 8.21 Million EUR | -1542.41% |
| genOway Société anonyme | 16.73 Million EUR | -706.08% |
| IntegraGen SA | 5.35 Million EUR | -2420.761% |
| Medesis Pharma S.A. | 1.56 Million EUR | -8523.7% |
| Neovacs S.A. | 10.34 Million EUR | -1204.427% |
| NFL Biosciences SA | 4.37 Million EUR | -2984.433% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -4779.975% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -7753.711% |
| Sensorion SA | 27.05 Million EUR | -398.727% |
| Theranexus Société Anonyme | 3 Million EUR | -4390.003% |
| TME Pharma N.V. | 5.49 Million EUR | -2354.502% |
| Valbiotis SA | 9.86 Million EUR | -1267.15% |
| TheraVet SA | 1.64 Million EUR | -8105.494% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -563.996% |
| DBV Technologies S.A. | 89.4 Million EUR | -50.912% |
| Genfit S.A. | 54.8 Million EUR | -146.194% |
| GeNeuro SA | 14.35 Million EUR | -839.759% |
| Innate Pharma S.A. | 64.57 Million EUR | -108.958% |
| Inventiva S.A. | 120.18 Million EUR | -12.263% |
| MaaT Pharma SA | 21.59 Million EUR | -524.706% |
| MedinCell S.A. | 32.92 Million EUR | -309.829% |
| Nanobiotix S.A. | 58.92 Million EUR | -128.968% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | -471.978% |
| Poxel S.A. | 28.76 Million EUR | -369.056% |
| GenSight Biologics S.A. | 32.66 Million EUR | -313.117% |
| Transgene SA | 31.23 Million EUR | -332.019% |